These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31124957)

  • 1. Evaluation of Y-site compatibility of home total parenteral nutrition and intravenous loop diuretics.
    Watrobska-Swietlikowska D; Pietka M; Klek S
    Medicine (Baltimore); 2019 May; 98(21):e15747. PubMed ID: 31124957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, open-label, blinded-endpoint, crossover, single-dose study to compare the pharmacodynamics of torasemide-PR 10 mg, torasemide-IR 10 mg, and furosemide-IR 40 mg, in patients with chronic heart failure.
    Ballester MR; Roig E; Gich I; Puntes M; Delgadillo J; Santos B; Antonijoan RM
    Drug Des Devel Ther; 2015; 9():4291-302. PubMed ID: 26273191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-Administration of Drugs and Parenteral Nutrition: In Vitro Compatibility Studies of Loop Diuretics for Safer Clinical Practice.
    Tomczak S; Stawny M; Jelińska A
    Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33202945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial).
    Trippel TD; Van Linthout S; Westermann D; Lindhorst R; Sandek A; Ernst S; Bobenko A; Kasner M; Spillmann F; González A; López B; Ravassa S; Pieske B; Paulus WJ; Díez J; Edelmann F; Tschöpe C
    Eur J Heart Fail; 2018 Mar; 20(3):460-470. PubMed ID: 28891228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro compatibility studies of vancomycin with ready-to-use parenteral nutrition admixtures for safer clinical practice.
    Stawny M; Nadolna M; Jelińska A
    Clin Nutr; 2020 Aug; 39(8):2539-2546. PubMed ID: 31784302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
    De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
    Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physicochemical Stability and Sterility of Standard Parenteral Nutrition Solutions and Simulated Y-Site Admixtures for Neonates.
    Riera P; Garrido-Alejos G; Cardenete J; Moliner E; Zapico-Muñiz E; Cardona D; Garin N
    Nutr Clin Pract; 2018 Oct; 33(5):694-700. PubMed ID: 29464781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physicochemical stability and compatibility testing of levetiracetam in all-in-one parenteral nutrition admixtures in daily practice.
    Aeberhard C; Steuer C; Saxer C; Huber A; Stanga Z; Mühlebach S
    Eur J Pharm Sci; 2017 Jan; 96():449-455. PubMed ID: 27742594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Torsemide versus furosemide after acute decompensated heart failure: a retrospective observational study.
    Rahhal A; Saad MO; Tawengi K; Assi AAR; Habra M; Ahmed D
    BMC Cardiovasc Disord; 2019 May; 19(1):127. PubMed ID: 31138146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Analysis of Long-Term Outcomes of Torasemide and Furosemide in Heart Failure Patients in Heart Failure Registries of the European Society of Cardiology.
    Ozierański K; Balsam P; Kapłon-Cieślicka A; Tymińska A; Kowalik R; Grabowski M; Peller M; Wancerz A; Marchel M; Crespo-Leiro MG; Maggioni AP; Drożdż J; Filipiak KJ; Opolski G
    Cardiovasc Drugs Ther; 2019 Feb; 33(1):77-86. PubMed ID: 30649675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Torasemide (LUPRAC): a review of its pharmacological and clinical profile].
    Kido H; Ohtaki Y
    Nihon Yakurigaku Zasshi; 2001 Aug; 118(2):97-105. PubMed ID: 11530685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites.
    Gentilini P; La Villa G; Marra F; Carloni V; Melani L; Foschi M; Cotrozzi G; Quartini M; Chibbaro G; Tommasi AC; Bernareggi A; Simoni A; Buzzelli G; Laffi G
    J Hepatol; 1996 Oct; 25(4):481-90. PubMed ID: 8912147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of torasemide on haemodynamic and neurohormonal stress, and cardiac remodelling in heart failure - TORNADO: a study protocol for a randomized controlled trial.
    Balsam P; Ozierański K; Tymińska A; Główczyńska R; Peller M; Fojt A; Cacko A; Sieradzki B; Bakuła E; Markulis M; Kowalik R; Huczek Z; Filipiak KJ; Opolski G; Grabowski M
    Trials; 2017 Jan; 18(1):36. PubMed ID: 28114980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Torasemide in advanced renal failure.
    Kindler J
    Cardiovasc Drugs Ther; 1993 Jan; 7 Suppl 1():75-80. PubMed ID: 8435381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the pharmacokinetics and diuretic effects of two loop diuretics, torasemide and furosemide, in normal volunteers.
    Dodion L; Ambroes Y; Lameire N
    Eur J Clin Pharmacol; 1986; 31 Suppl():21-7. PubMed ID: 3780837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of loop diuretics on mortality in the treatment of patients with chronic heart failure - A multicenter propensity score matched analysis.
    Täger T; Fröhlich H; Grundtvig M; Seiz M; Schellberg D; Goode K; Kazmi S; Hole T; Katus HA; Atar D; Cleland JGF; Agewall S; Clark AL; Frankenstein L
    Int J Cardiol; 2019 Aug; 289():83-90. PubMed ID: 30827731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diuretic activity of torasemide and furosemide in chronic heart failure: a comparative double blind cross-over study.
    Scheen AJ; Vancrombreucq JC; Delarge J; Luyckx AS
    Eur J Clin Pharmacol; 1986; 31 Suppl():35-42. PubMed ID: 3780838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Torasemide. A review of its pharmacological properties and therapeutic potential.
    Friedel HA; Buckley MM
    Drugs; 1991 Jan; 41(1):81-103. PubMed ID: 1706990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physical compatibility of medications with concentrated neonatal and pediatric parenteral nutrition: A simulated Y-site drug compatibility study.
    Ross EL; Petty K; Salinas A; Her C; Carpenter JF
    JPEN J Parenter Enteral Nutr; 2023 Mar; 47(3):372-381. PubMed ID: 36582024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Torasemide--new generation loop diuretic: clinical pharmacology and therapeutic application].
    Preobrazhenskiĭ DV; Sidorenko BA; Tarykina EV; Batyraliev TA; Marenich AV
    Kardiologiia; 2006; 46(10):75-86. PubMed ID: 17159856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.